Annisa Firdaus Sutendi

Annisa Firdaus Sutendi

Auto-generated profile, based on publicly available information

Annisa Firdaus Sutendi

Aretha Medika Utama, Biomolecular and Biomedical Research Center, Bandung, 40163, West Java, Indonesia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
WWWahyu Widowati
Wahyu Widowati
ASAdilah Hafizha Nur Sabrina
Adilah Hafizha Nur Sabrina
ASAnnisa Firdaus Sutendi
Annisa Firdaus Sutendi
FZFadhilah Haifa Zahiroh
Fadhilah Haifa Zahiroh
ANAris Muhamad Nurjamil
Aris Muhamad Nurjamil
Massoud VosoughMassoud Vosough
Massoud Vosough
Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.